What is the rationale for more concentrated basal insulins -- U200 degludec and U300 insulin glargine -- and what advantages do they offer in glycemic control and hypoglycemia risk?

What is the rationale for more concentrated basal insulins -- U200 degludec and U300 insulin glargine -- and what advantages do they offer in glycemic control and hypoglycemia risk?

What is the rationale for deploying more concentrated basal insulins — U200 degludec and U300 insulin glargine — and what advantages do they offer with respect to physiologic glycemic control and hypoglycemia risk?


Created by

CMEducation Resources IQ&A Interactive Intelligence Zone

Presenter

Chantal Mathieu, MD, PhD

Chantal Mathieu, MD, PhD

Professor of Medicine
Program Director of Biomedical Sciences
Katholieke Universiteit
Chair of Endocrinology
University Hospital Gasthuisberg
Leuven, Belgium